The Efficacy of Metformin Produced by Pars Mino Co in Comparison With Canadian Apotex Co. in Glycemic Control of Diabetic Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01228240|
Recruitment Status : Completed
First Posted : October 26, 2010
Last Update Posted : October 26, 2010
Background: Metformin is usually using for glycemic control in type 2 diabetes mellitus. Different pharmaceutical types of metformin are available. As a clinical trial, we compared the efficacy and complications of metformin produced by "Pars Mino pharmaceutical company, Iran" with "Apotex pharmaceutical company, Canada", in type 2 diabetic patients.
Method: 18 eligible women with type 2 diabetes were given metformin "Pars Mino" or "Apotex" (500 mg twice a day) each for 6 weeks period in a randomized, double blind, crossover study. After 2 weeks washout period another 6 weeks period with another Brand of metformin was prescribed. FBS, HbA1C, lipid profile (Cholesterol, TG, HDL, and LDL), weight, and BMI were assessed before and after each treatment phase. The results were compared with each other by paired sample T-test, Independent sample T-test.
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus, Type 2 AND Metformin||Drug: Metformin||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Study Start Date :||December 2008|
|Actual Primary Completion Date :||July 2009|
|Actual Study Completion Date :||September 2009|
|Experimental: Metformin, Apo-metformin||